Conrad Vinalon
Family Medicine · St Petersburg, FLNPI 1174960694
Payments from drug & device makers
Across 131 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$296
- AstraZeneca$260
- Lilly USA, LLC$211
- Pfizer$164
- Merck$162
- Boehringer Ingelheim$141
- plus $737 from 14 others
What the payments were for
- Food & beverage$1,963100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $296 |
| AstraZeneca | 16 | $260 |
| Lilly USA, LLC | 14 | $211 |
| Pfizer | 15 | $164 |
| Merck | 12 | $162 |
| Boehringer Ingelheim | 10 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
| AbbVie(2 entities) | 6 | $124 |
| GSK | 5 | $113 |
| Amgen | 6 | $93 |
| Johnson & Johnson | 7 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Medtronic | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,971 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $89,216 |
| EliquisApixaban | 99 | $64,658 |
| JulucaDolutegravir/Rilpivirine | 11 | $37,862 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 223 | $27,282 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,512 |
| JanuviaSitagliptin Phosphate | 22 | $24,026 |
| JardianceEmpagliflozin | 13 | $19,441 |
| XareltoRivaroxaban | 11 | $18,028 |
| TrulicityDulaglutide | 16 | $15,402 |
| MultaqDronedarone Hcl | 19 | $14,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 397 | $11,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,119 |
| Gabapentin | 195 | $5,306 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 14 | $4,666 |
| Fenofibrate | 22 | $4,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $296 | $91,372106 claims |
| PfizerEliquis | $164 | $64,65899 claims |
| MerckJanuvia | $162 | $24,02622 claims |
| Boehringer IngelheimJardiance | $141 | $19,44113 claims |
| Sanofi-aventis U.S. LLCMultaq, Lantus | $19 | $18,40840 claims |
| Johnson & JohnsonXarelto | $90 | $18,02811 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $211 | $16,72833 claims |
| GSKTrelegy Ellipta | $113 | $8,11911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in St Petersburg
- Gigi LefebvreSt Petersburg$9.2M
- Roxana StoiciSt Petersburg$9.1M
- Linda MurraySt Petersburg$4.1M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.